Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics May 6, 2025
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program May 6, 2025
Adagene Achieves $3M Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked ADC May 5, 2025
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals April 30, 2025
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies April 30, 2025
Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of TCR-NK Therapy ZI-MA4-1 Targeting Solid Tumours April 30, 2025
Innate Pharma regains rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company April 30, 2025
Veraxa and Voyager to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Gen Cancer Therapies April 30, 2025
FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg) April 30, 2025
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop a Multimodal Foundation Model in Oncology April 30, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers April 30, 2025
Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast April 30, 2025
Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform April 30, 2025
Sumitomo Pharma America enters into a CRADA with the NCI to Advance Clinical Understanding of Enzomenib April 22, 2025
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Pan-Isotype Cancer Antibody Company April 16, 2025
Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies April 16, 2025
Scancell Holdings announces partnership with the NHS CVLP to fast-track access for NHS patients into 4th cohort of Ph 2 SCOPE study April 15, 2025
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals April 15, 2025
